



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 311/00		A2	(11) International Publication Number: WO 98/42659
			(43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/EP98/01766 (22) International Filing Date: 16 March 1998 (16.03.98) (30) Priority Data: 9706255.8 26 March 1997 (26.03.97) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): FALLER, Andrew [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). (74) Agent: WEST, Vivien; SmithKline Beecham plc, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: NOVEL COMPOUNDS			
(57) Abstract			
<p>Compounds of formula (I) wherein R is hydroxy, hydrogen, alkenyl, alkynyl or aryl, and R₁ is aryl or heteroaryl, are useful in the treatment and prophylaxis of conditions mediated by CD23 or TNF.</p>			
<chem>NC(=O)C(R)NS(=O)(=O)R1</chem> (I)			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Novel Compounds

This invention relates to novel inhibitors of the formation of soluble human CD23 and their use in the treatment of conditions associated with excess production of soluble
5 CD23 (s-CD23) such as autoimmune disease and allergy.

CD23 (the low affinity IgE receptor FcεRII, Blast 2), is a 45 kDa type II integral protein expressed on the surface of a variety of mature cells, including B and T lymphocytes, macrophages, natural killer cells, Langerhans cells, monocytes and platelets (Delespesse *et al*, *Adv Immunol*, 49 [1991] 149-191). There is also a CD23-like molecule on eosinophils
10 (Grangette *et al*, *J Immunol*, 143 [1989] 3580-3588). CD23 has been implicated in the regulation of the immune response (Delespesse *et al*, *Immunol Rev*, 125 [1992] 77-97). Human CD23 exists as two differentially regulated isoforms, a and b, which differ only in the amino acids at the intracellular N-terminus (Yokota *et al*, *Cell*, 55 [1988] 611-618). In man the constitutive a isoform is found only on B-lymphocytes, whereas type b, inducible by IL4,
15 is found on all cells capable of expressing CD23.

Intact, cell bound CD23 (i-CD23) is known to undergo cleavage from the cell surface leading to the formation of a number of well-defined soluble fragments (s-CD23), which are produced as a result of a complex sequence of proteolytic events, the mechanism of which is still poorly understood (Bourget *et al* *J Biol Chem*, 269 [1994] 6927-6930). Although not yet
20 proven, it is postulated that the major soluble fragments (Mr 37, 33, 29 and 25 kDa) of these proteolytic events, all of which retain the C-terminal lectin domain common to i-CD23, occur sequentially via initial formation of the 37 kDa fragment (Letellier *et al*, *J Exp Med*, 172 [1990] 693-700). An alternative intracellular cleavage pathway leads to a stable 16 kDa fragment differing in the C-terminal domain from i-CD23 (Grenier-Brossette *et al*, *Eur J*
25 *Immunol*, 22 [1992] 1573-1577).

Several activities have been ascribed to membrane bound i-CD23 in humans, all of which have been shown to play a role in IgE regulation. Particular activities include: a) antigen presentation, b) IgE mediated eosinophil cytotoxicity, c) B cell homing to germinal centres of lymph nodes and spleen, and d) downregulation of IgE synthesis (Delespesse *et al*,
30 *Adv Immunol*, 49, [1991] 149-191). The three higher molecular weight soluble CD23 fragments (Mr 37, 33 and 29 kDa) have multifunctional cytokine properties which appear to play a major role in IgE production. Thus, the excessive formation of s-CD23 has been

implicated in the overproduction of IgE, the hallmark of allergic diseases such as extrinsic asthma, rhinitis, allergic conjunctivitis, eczema, atopic dermatitis and anaphylaxis (Sutton and Gould, *Nature*, 366, [1993] 421-428).

Other biological activities attributed to s-CD23 include the stimulation of B cell growth and the induction of the release of mediators from monocytes. Thus, elevated levels of s-CD23 have been observed in the serum of patients having B-chronic lymphocytic leukaemia (Sarfati *et al*, *Blood*, 71 [1988] 94-98) and in the synovial fluids of patients with rheumatoid arthritis (Chomarat *et al*, *Arthritis and Rheumatism*, 36 [1993] 234-242). That there is a role for CD23 in inflammation is suggested by a number of sources. First, sCD23 has been reported to bind to extracellular receptors which when activated are involved in cell-mediated events of inflammation. Thus, sCD23 is reported to directly activate monocyte TNF, IL-1, and IL-6 release (Armant *et al*, vol 180, *J.Exp. Med.*, 1005-1011 (1994)). CD23 has been reported to interact with the B2-integrin adhesion molecules, CD11b and CD11c on monocyte/macrophage (S. Lecoanet-Henchoz *et al*, *Immunity*, vol 3; 119-125 (1995)) which trigger NO₂⁻, hydrogen peroxide and cytokine (IL-1, IL-6, and TNF) release. Finally, IL-4 or IFN induce the expression of CD23 and its release as sCD23 by human monocytes. Ligation of the membrane bound CD23 receptor with IgE/anti-IgE immune complexes or anti CD23 mAb activates cAMP and IL-6 production and thromboxane B2 formation, demonstrating a receptor-mediated role of CD23 in inflammation.


Because of these various properties of CD23, compounds which inhibit the formation of s-CD23 should have twofold actions of a) enhancing negative feedback inhibition of IgE synthesis by maintaining levels of i-CD23 on the surface of B cells, and b) inhibiting the immunostimulatory cytokine activities of higher molecular weight soluble fragments (Mr 37, 33 and 29 kDa) of s-CD23. In addition, inhibition of CD23 cleavage should mitigate sCD23-induced monocyte activation and mediator formation, thereby reducing the inflammatory response.

TNF α is a pro-inflammatory cytokine which is released from stimulated cells by specific cleavage of a 76-amino acid signal sequence in the inactive precursor to generate the mature form. The cleavage of TNF α has been reported to be carried out by a metalloprotease (Gearing, A.J.H. *et al*, (1994) *Nature* 370, 555-557; McGeehan, G.M. *et al*, (1994) *Nature* 370, 558-561; Mohler, K.M. *et al*, (1994) *Nature* 370, 218-220). Compounds

reported to inhibit the cleavage of $\text{TNF}\alpha$ by the TNF processing enzyme can be broadly described as matrix metalloprotease inhibitors, particularly of the hydroxamic acid class. .

$\text{TNF}\alpha$ is induced in a variety of cell types in response to bacteria, endotoxin, various viruses and parasites, so that one physiological function ascribed to $\text{TNF}\alpha$ is a contribution to the inflammatory response to acute infection by bacteria, parasites, etc (Dinarello, C.A. (1992) Immunol. 4, 133-145). Overproduction of $\text{TNF}\alpha$ has been implicated in disease states such as rheumatoid arthritis, septic shock, Crohn's disease and cachexia (Dinarello, 1992). Inhibition of processing of $\text{TNF}\alpha$ to the mature, active form would therefore be beneficial in the treatment of these inflammatory disorders. $\text{TNF}\alpha$ may also contribute to the destruction of tissue in autoimmune disease although it is not an initiating factor in these diseases. Confirming the importance of $\text{TNF}\alpha$ in rheumatoid arthritis, $\text{TNF}\alpha$ antibodies have been shown to reduce the severity of disease in short term studies in rheumatoid arthritis models (Elliott, M.J., et al (1993) Arthrit. Rheum. 12, 1681-1690; Elliott et al (1994) Lancet 344, 1125-1127).

According to the present invention, there is provided a compound of formula (I):



(I)

wherein R is hydroxy, hydrogen, alkenyl, alkynyl or aryl, and R1 is aryl or heteroaryl.

Alkyl, alkenyl and alkynyl groups referred to herein include straight and branched groups containing up to six carbon atoms and are optionally substituted by one or more groups selected from the group consisting of aryl, heterocyclyl, (C_{1-6}) alkylthio, (C_{2-6}) alkenylthio, (C_{2-6}) alkynylthio, arylthio, heterocyclylthio, (C_{1-6}) alkoxy, aryl (C_{1-6}) alkoxy, aryl (C_{1-6}) alkylthio, amino, mono- or di- (C_{1-6}) alkylamino, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy, and halogen.

Cycloalkyl and cycloalkenyl groups referred to herein include groups having between three and eight ring carbon atoms and are optionally substituted as described hereinabove for alkyl, alkenyl and alkynyl groups.

When used herein, the term "aryl" includes phenyl and naphthyl such as 2-naphthyl.

Suitably any aryl group, including phenyl and naphthyl, may be optionally substituted by up

to five, preferably up to three substituents. Suitable substituents include halogen, (C₁₋₆)alkyl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, hydroxy, nitro, amino, mono- and di-*N*-(C₁₋₆)alkylamino, acylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-*N*-(C₁₋₆)alkylcarbamoyl, (C₁₋₆)alkoxycarbonyl, aryloxycarbonyl, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkyl sulphinyl (C₁₋₆)alkylsulphonyl, heterocyclyl and heterocyclyl (C₁₋₆)alkyl. In addition, two adjacent ring carbon atoms may be linked by a (C₃₋₅)alkylene chain, to form a carbocyclic ring. Thus, the term "aryl" includes single and fused rings, of which at least one is aromatic, which rings may be unsubstituted or substituted by, for example, up to three substituents as set out above. Each ring suitably has from 4 to 7, preferably 5 or 6, ring atoms.

When used herein the terms "heterocyclyl" and "heterocyclic" suitably include, unless otherwise defined, aromatic and non-aromatic, single and fused, rings suitably containing up to four heteroatoms in each ring, each of which is selected from oxygen, nitrogen and sulphur, which rings, may be unsubstituted or substituted by, for example, up to three substituents. Each ring suitably has from 4 to 7, preferably 5 or 6, ring atoms. A fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.

When used herein the term "heteroaryl" suitably includes any heterocyclyl group which incorporates at least one aromatic ring (heterocyclic or carbocyclic).

Preferably a substituent for a heterocyclyl group is selected from halogen, (C₁₋₆)alkyl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, hydroxy, amino, mono- and di-*N*-(C₁₋₆)alkyl-amino, acylamino, carboxy salts, carboxy esters, carbamoyl, mono- and di-*N*-(C₁₋₆)alkylcarbonyl, aryloxycarbonyl, (C₁₋₆)alkoxycarbonyl(C₁₋₆)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkylsulphinyl, (C₁₋₆)alkylsulphonyl, heterocyclyl and heterocyclyl(C₁₋₆)alkyl.

In a particular aspect of the invention, R is isopropyl; isobutyl, or 4-(trifluoroacetamido)butyl, and/or R₁ is a phenyl group, optionally substituted, for example by methoxy, such as 4-methoxyphenyl, or a fused aromatic group such as 2-naphthyl, or 5-(2-pyridyl)thiophen-2-yl.

According to a further aspect, the present invention provides the use of a compound of formula (I) for the production of a medicament for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders, and autoimmune disease, in which the overproduction of s-CD23 is implicated.

5 In a further aspect the invention provides a method for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders, and autoimmune disease, in which the overproduction of s-CD23 is implicated, which method comprises the administration of a compound of formula (I), to a human or non-human mammal in need thereof.

The invention also provides a pharmaceutical composition for the treatment or
10 prophylaxis of disorders such as allergy, inflammatory disorders, and autoimmune disease, in which the overproduction of s-CD23 is implicated which comprises a compound of formula (I) and optionally a pharmaceutically acceptable carrier therefor.

Particular inflammatory disorders include CNS disorders such as Alzheimers disease, multiple sclerosis, and multi-infarct dementia, as well as the inflammation mediated sequelae
15 of stroke and head trauma.

According to a further aspect, the present invention provides the use of a compound of formula (I) for the production of a medicament for the treatment or prophylaxis of conditions mediated by TNF, including, but not limited to, inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia and
20 anorexia, acute infections, shock states, graft versus host reactions and autoimmune disease.

In a further aspect the invention provides a method for the treatment or prophylaxis of conditions mediated by TNF, which method comprises the administration of a compound of formula (I), to a human or non-human mammal in need thereof.

The invention also provides a pharmaceutical composition for the treatment or
25 prophylaxis of conditions mediated by TNF, which comprises a compound of formula (I) and optionally a pharmaceutically acceptable carrier therefor.

The present inventors have surprisingly found that the compounds of the invention are potent and selective inhibitors of both CD23 processing and TNF processing, whilst having little or no activity as inhibitors of matrix metalloproteases. A further aspect of the
30 invention thus provides the use of a TNF processing inhibitor for the production of a medicament for the treatment or prophylaxis of conditions mediated by sCD23, characterised in that the TNF processing inhibitor is not an inhibitor of matrix metalloprotease.

It is to be understood that the pharmaceutically acceptable salts, solvates and other pharmaceutically acceptable derivatives of the compound of formula (I) are also included in the present invention.


Salts of compounds of formula (I) include for example acid addition salts derived from inorganic or organic acids, such as hydrochlorides, hydrobromides, hydroiodides, p-toluenesulphonates, phosphates, sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

Salts may also be formed with bases. Such salts include salts derived from inorganic or organic bases, for example alkali metal salts such as sodium or potassium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

The compounds of the invention may be prepared by use of any appropriate conventional method, for example by analogy with the methods disclosed in patent publication EP-A-0 606 046.

Accordingly, a further aspect of the invention provides a process for preparing a compound of formula (I) as defined hereinabove, which process comprises:


(a) deprotecting a compound of formula (II):



(II)

wherein R and R1 are as defined hereinabove, and X is a protecting group such as benzyl or trimethylsilyl or

(b) reacting a compound of formula (III):




(III)

wherein R and R1 are as defined hereinabove, with hydroxylamine or a salt thereof, or

(c) converting a compound of formula (I) to a different compound of formula (I) as defined hereinabove.

Compounds of formula (II) are novel and form a further aspect of the invention.

Compounds of formula (II) can be prepared from compounds of formula (III) by
 5 reaction with a protected hydroxylamine. Compounds of formula (III) can be prepared by hydrolysis of a compound of formula (IV):



10


(IV)

wherein R and R1 are as defined hereinabove, and Y is a protecting group such as t-butyl.

Suitable protecting groups for a hydroxamic acid are well known in the art and include benzyl, trimethylsilyl, t-butyl and t-butyldimethylsilyl.

Suitable protecting groups for a carboxylic acid are well known in the art and include
 15 t-butyl, benzyl and methyl.

Compounds of formula (IV) can be prepared by reacting a compound of formula (V):




(V)

20 wherein R and Y are as defined hereinabove, with a compound of formula R^1SO_3H , wherein R1 is as defined hereinabove, or an activated derivative thereof, such as an arylsulfonyl chloride.

The starting materials and other reagents are available commercially or can be synthesised by well-known and conventional methods.

25 The isomers, including stereoisomers, of the compounds of the present invention may be prepared as mixtures of such isomers or as individual isomers. The individual isomers may be prepared by any appropriate method, for example individual

stereoisomers may be prepared by stereospecific chemical synthesis starting from chiral substrates or by separating mixtures of diastereoisomers using known methods. In a preferred aspect, the invention provides compounds of formula (IA):



(1A)

It is preferred that the compounds are isolated in substantially pure form.

As stated herein an inhibitor of the formation of soluble human CD23 has useful medical properties. Preferably the active compounds are administered as pharmaceutically acceptable compositions.

The compositions are preferably adapted for oral administration. However, they may be adapted for other modes of administration, for example in the form of a spray, aerosol or other conventional method for inhalation, for treating respiratory tract disorders; or parenteral administration for patients suffering from heart failure. Other alternative modes of administration include sublingual or transdermal administration.

The compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose.

Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.

The solid oral compositions may be prepared by conventional methods of blending, filling or tableting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.

Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

Compositions of this invention may also suitably be presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case the particles of active compound suitably have diameters of less than 50 microns, preferably less than 10 microns for example diameters in the range of

1-50 microns, 1-10 microns or 1-5 microns. Where appropriate, small amounts of other anti-asthmatics and bronchodilators, for example sympathomimetic amines such as isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine; xanthine derivatives such as theophylline and aminophylline and corticosteroids such as prednisolone and adrenal stimulants such as ACTH may be included.

The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration. A preferred range for inhaled administration is 10-99%, especially 60-99%, for example 90, 95 or 99%.

Microfine powder formulations may suitably be administered in an aerosol as a metered dose or by means of a suitable breath-activated device.

Suitable metered dose aerosol formulations comprise conventional propellants, cosolvents, such as ethanol, surfactants such as oleyl alcohol, lubricants such as oleyl alcohol, desiccants such as calcium sulphate and density modifiers such as sodium chloride.


Suitable solutions for a nebulizer are isotonic sterilised solutions, optionally buffered, at for example between pH 4-7, containing up to 20mg/ml of compound but more generally 0.1 to 10mg/ml, for use with standard nebulisation equipment.

An effective amount will depend on the relative efficacy of the compounds of the present invention, the severity of the disorder being treated and the weight of the sufferer. Suitably, a unit dose form of a composition of the invention may contain from 0.1 to 1000mg of a compound of the invention (0.001 to 10mg via inhalation) and more usually from 1 to 500mg, for example 1 to 25 or 5 to 500mg. Such compositions may be administered from 1 to 6 times a day, more usually from 2 to 4 times a day, in a manner such that the daily dose is from 1mg to 1g for a 70 kg human adult and more particularly from 5 to 500mg. That is in the range of about 1.4×10^{-2} mg/kg/day to 14 mg/kg/day and more particularly in the range of about 7×10^{-2} mg/kg/day to 7 mg/kg/day.


The following examples illustrate the invention but do not limit it in any way.

Example 1**2-(R)-N-Hydroxy-[(4-Methoxybenzene)sulfonyl]amino-3-methylbutyramide**

5

**a) 2-(R)-N-[(4-methoxybenzene)sulfonyl]valine**

10




- 15 To a solution of D-valine (10g, 85.4 mmol) in 1,4-dioxan (200 ml) and water (100 ml) at 0°C was added triethylamine (59 ml, 427 mmol) followed by 4-methoxybenzene sulfonylchloride (21g, 102 mmol). The solution was allowed to warm to ambient temperature and stirred for 2 days. The organic solvent was removed at reduced pressure and the residue made alkaline with sodium bicarbonate. This solution was extracted with ethyl acetate, then
- 20 acidified using 2N HCl and extracted with ethyl acetate (x2). These extracts were dried and the solvent removed under reduced pressure to give the title compound (22.1g, 90%) as a white solid.

¹H nmr (d₆-DMSO) 0.74 (6H, d, J = 6.9 Hz), 1.68-1.99 (1H, m), 3.20-3.28 (1H, m), 3.82 (3H, s), 7.04 (2H, d, J = 9 Hz), 7.68 (2H, d, J = 9 Hz), 7.66-7.73 (1H, br), 10.7 (1H, br).

b) 2-(R)-N-Hydroxy-[(4-Methoxybenzene)sulfonyl]amino-3-methylbutyramide

5




To a solution of 2-(R)-N-[(4-methoxybenzene)sulfonyl]valine (1g, 3.5 mmol) in DMF (72 ml) was added 1-hydroxy-7-azabenzotriazole (HOAt, 629 mg, 4.5 mmol), 1-(3-dimethylaminopropyl)3-ethylcarbodiimide hydrochloride (DEC, 879 mg, 4.5 mmol), hydroxylamine hydrochloride (278 mg, 3.8 mmol) and N-methylmorpholine (0.5 ml, 3.8 mmol) and the solution stirred for 18h. The solvent was removed under reduced pressure and the residue dissolved in ethyl acetate then washed with citric acid (10% solution), sodium bicarbonate (satd) and brine. The solution was dried and concentrated under reduced pressure to give a yellow foam which was triturated with diethyl ether to yield a white solid (0.5g, 48%)

MH⁺ 303, MNa⁺ 325

20

¹H nmr (d₆-DMSO) 0.73 (6H, d, J = 6.9 Hz), 1.68-1.99 (1H, m), 3.21-3.28 (1H, m), 3.82 (3H, s), 7.04 (2H, d, J = 8.8 Hz), 7.68 (2H, d, J = 8.8 Hz), 7.66-7.73 (1H, br), 8.77 (1H, s), 10.47 (1H, s).

Example 2**2-(R)-N-Hydroxy-[(2-naphthyl)sulfonyl]amino-3-methylbutyramide**

5


This was prepared from 2-(R)-N-[(4-methoxybenzene)sulfonyl]valine and 2-naphthylsulfonylchloride by the procedure of example 1 b (45%) as a cream solid.

10

MNH_4^+ 340

^1H nmr (d_6 -DMSO) 0.71-0.76 (6H, m), 1.74-1.81 (1H, m), 3.27-3.36 (1H, m), 7.63-7.68 (2H, m), 7.80 (1H, d, $J = 8.5$ Hz), 8.01-8.12 (4H, m), 8.37 (1H, s), 8.75 (1H, s), 10.51 (1H, s).


15

Example 3**a) N((5-(2-pyridyl)thiophen-2-ylsulfonyl)-(R)-leucine**

20 The title compound was prepared as in Example 1.

NMR: (DMSO-d_6) δ 0.80 (3H, d, $J = 6.5$ Hz), 0.87 (3H, d, $J = 6.5$ Hz), 1.46 (2H, m), 1.66 (1H, septet, $J = 6.3$ Hz), 3.79 (1H, m), 7.41 (1H, m), 7.59 (1H, d, $J = 4$ Hz), 7.84 (1H, d, $J = 4$ Hz), 7.94 (1H, m), 8.07 (1H, d, $J = 8$ Hz), 8.45 (1H, v. br. s), 8.62 (1H, d, $J = 4.2$ Hz); **MS:** ($M + H$) = 355


25

b) N-hydroxy-N α ((5-(2-pyridyl)thiophen-2-ylsulfonyl)-(R)-leucinamide

The title compound was prepared as in Example 1

- 5 NMR: (DMSO-d₆) δ 0.70 (1H, d, J = 6.4 Hz), 0.78 (1H, d, J = 6.4 Hz), 1.33 (2H, m), 1.47 (1H, septet, J = 6.4 Hz), 3.65 (1H, m), 7.38 (1H, m), 7.54 (1H, d, J = 4 Hz), 7.80 (1H, d, J = 4 Hz), 7.90 (1H, m), 8.02 (1H, d, J = 7.9 Hz), 8.30 (1H, br., d), 8.59 (1H, d, J = 4.2 Hz), 8.87 (1H, s), 10.72 (1H, s); MS: (M + H) = 370.

10 Example 4


a) N ϵ -*tert*butoxycarbonyl-N α ((5-(2-pyridyl)thiophen-2-ylsulfonyl)-(R)-lysine

The title compound was prepared as in Example 1

15

- NMR: (DMSO-d₆) δ 1.22 - 1.42 (4H, br., m), 1.41 (9H, s), 1.50 - 1.75 (2H, br., m), 2.88 (2H, br. q, J \approx 6 Hz), 3.79 (1H, m), 6.76 (1H, br., t), 7.44 (1H, m), 7.61 (1H, d, J = 4 Hz), 7.86 (1H, d, J = 4 Hz), 7.96 (1H, m), 8.08 (1H, d, J = 8 Hz), 8.64 (1H, d J = 4.2 Hz); MS: (M + H) = 470.

b) *N*-*tert*butoxycarbonyl-N-hydroxy- $N\alpha$ -(5-(2-pyridyl)thiophen-2-ylsulfonyl)-(R)-lysineamide




The title compound was prepared as in Example 1

5

NMR: (DMSO- d_6) δ 1.0 - 1.36 (4H, br., m), 1.36-1.56 (2H, br., m), 1.36 (9H, s), 2.79 (2H, br. q, $J \approx 6$ Hz), 3.67 (1H, br. m), 6.70 (1H, br., t), 7.40 (1H, m), 7.56 (1H, d, $J = 4$ Hz), 7.82 (1H, d, $J = 4$ Hz), 7.93 (1H, m), 8.04 (1H, d, $J = 8$ Hz), 8.33 (1H, d, $J = 7$ Hz, SO_2NH), 8.60 (1H, d, $J = 4.2$ Hz), 8.89 (1H, s), 10.64 (1H, s); **MS:** ($M + H$) = 485.

10

c) N-hydroxy- $N\alpha$ -(5-(2-pyridyl)thiophen-2-ylsulfonyl)-(R)-lysineamide trifluoroacetate salt



15


The title compound was prepared by treatment of *N*-*tert*butoxycarbonyl-N-hydroxy- $N\alpha$ -(5-(2-pyridyl)thiophen-2-ylsulfonyl)-(R)-lysineamide with trifluoroacetic acid: dichloromethane (1:1) until all starting material had disappeared (tlc), then removal of volatiles.

20

NMR: (DMSO- d_6) δ 1.1 - 1.65 (6H, br., m), 2.75 (2H, m), 3.71 (1H, br., q), 7.25 (1H, m), 7.45 (1H, m), 7.61 (1H, d, $J = 4$ Hz), 7.68 (~2H, br., s), 7.88 (1H, d, $J = 4$ Hz), 7.98 (1H, m), 8.11 (1H, d, $J = 8$ Hz), 8.43 (1H, d, $J = 8.5$ Hz), 8.65 (1H, d, $J = 4.2$ Hz), 10.75 (1H, s); **MS:** ($M + H$) = 385.

Claims

1. A compound of formula (I):



(I)

wherein R is hydroxy, hydrogen, alkenyl, alkynyl or aryl, and R₁ is aryl or heteroaryl.

2. A compound according to claim 1 wherein R is isopropyl; isobutyl, or 4-(trifluoroacetamido)butyl, and/or R₁ is a phenyl group, optionally substituted, or a fused aromatic group, or 5-(2-pyridyl)thiophen-2-yl.
3. A compound selected from the group consisting of
 2-(R)-N-Hydroxy-[(4-Methoxybenzene)sulfonyl]amino-3-methylbutyramide
 2-(R)-N-Hydroxy-[(2-naphthyl)sulfonyl]amino-3-methylbutyramide
 N-hydroxy-Nα((5-(2-pyridyl)thiophen-2-ylsulfonyl)-(R)-leucinamide
 N-hydroxy- Nα(5-(2-pyridyl)thiophen-2-ylsulfonyl)-(R)-lysineamide trifluoroacetate salt
4. Use of a compound according to any preceding claim for the production of a medicament for the treatment or prophylaxis of disorders in which the overproduction of s-CD23 is implicated.
5. A method for the treatment or prophylaxis of disorders in which the overproduction of s-CD23 is implicated, which method comprises the administration of a compound according to any one of claims 1 to 3 to a human or non-human mammal in need thereof.
6. A pharmaceutical composition for the treatment or prophylaxis of disorders in which the overproduction of s-CD23 is implicated which comprises a compound according to any one of claims 1 to 3 and optionally a pharmaceutically acceptable carrier therefor.

7. Use of a compound according to any one of claims 1 to 3 for the production of a medicament for the treatment or prophylaxis of conditions mediated by TNF.


8. A method for the treatment or prophylaxis of conditions mediated by TNF, which method comprises the administration of a compound according to any one of claims 1 to 3 to a human or non-human mammal in need thereof.

9. A pharmaceutical composition for the treatment or prophylaxis of conditions mediated by TNF, which comprises a compound according to any one of claims 1 to 3 and optionally a pharmaceutically acceptable carrier therefor.

10. Use of a TNF processing inhibitor for the production of a medicament for the treatment or prophylaxis of conditions mediated by sCD23, characterised in that the TNF processing inhibitor is not an inhibitor of matrix metalloprotease.

11. A process for preparing a compound according to any one of claims 1 to 3 which process comprises:


(a) deprotecting a compound of formula (II):



(II)

wherein R and R1 are as defined hereinabove, and X is a protecting group, or

(b) reacting a compound of formula (III):




(III)

wherein R and R1 are as defined hereinabove, with hydroxylamine or a salt thereof, or

(c) converting a compound of formula (I) to a different compound of formula (I) as defined hereinabove.

12. A compound of formula (II):

5



(II)

wherein R and R₁ are as defined hereinabove, and X is a protecting group.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 311/29, C07D 409/04, C07C 311/19, A61K 31/18, 31/44	A3	(11) International Publication Number: WO 98/42659 (43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/EP98/01766 (22) International Filing Date: 16 March 1998 (16.03.98) (30) Priority Data: 9706255.8 26 March 1997 (26.03.97) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): FALLER, Andrew [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). (74) Agent: WEST, Vivien; SmithKline Beecham plc, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 25 February 1999 (25.02.99)	
(54) Title: ARYL- OR HETEROARYLSULFONAMIDE SUBSTITUTED HYDROXAMIC ACID DERIVATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS (57) Abstract Compounds of formula (I) wherein R is hydroxy, hydrogen, alkenyl, alkynyl or aryl, and R ₁ is aryl or heteroaryl, are useful in the treatment and prophylaxis of conditions mediated by CD23 or TNF. <div style="text-align: center; margin-top: 20px;"> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/01766

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C311/29 C07D409/04 C07C311/19 A61K31/18 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 35276 A (BRITISH BIOTECH PHARMACEUTICALS LTD) 28 December 1995 see page 3, last paragraph; page 23, lines 3-4 and example 9	1,7-9, 11,12
Y	see page 3, line 15 - page 6, line 1; page 16, line 17 - page 19, line 7	4-6
Y	--- WO 96 02240 A (SMITHKLINE BEECHAM PLC) 1 February 1996 see claims 1,2,4-6,8	4-6
X	--- WO 97 05865 A (FIBROGEN INC) 20 February 1997 see claims 1,16; example 6.1.13	1,11,12
A	see claims 1,16,19-24 --- -/--	4,7



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 December 1998

Date of mailing of the international search report

13/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Amsterdam, L

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/01766

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 757 984 A (ONO PHARMACEUTICAL CO LTD) 12 February 1997 see tables, in particular table 4; examples 1-3; claims 1-4, 12	1,2,11, 12
A	see page 42, line 46 - page 44, line 14; claims	4,7
X	----- DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US STN, accession no. 70:88228, XP002074847 see abstract; RN 21753-34-4 & N. YONEDA ET AL: YAKUGAKU ZASSHI, vol. 89, no. 1, 1969, pages 98-103, -----	1
X	DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US STN, accession no. 112:179786, XP002074848 see abstract; RN 126245-64-5, 126245-65-6, 126372-69-8 & S. NATELSON ET AL: MICROCHEM. J., vol. 40, no. 2, 1989, pages 226-232, -----	1
A	EP 0 606 046 A (CIBA-GEIGY AG) 13 July 1994 cited in the application see claims	1,2,4,7, 11,12
P,X	----- WO 98 09934 A (WARNER-LAMBERT CO) 12 March 1998 see page 26, scheme; example 10; claims 34-35	1,2,11, 12
P,A	----- WO 97 44315 A (WARNER-LAMBERT CO) 27 November 1997 see pages 15-19; claims 1, 2, 3, 12, 14, 16-18 -----	1,4-9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/01766

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 5,8
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 5 and 8
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/01766

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9535276 A	28-12-1995	AU 695507 B	13-08-1998
		AU 2746595 A	15-01-1996
		AU 690703 B	30-04-1998
		AU 2746695 A	15-01-1996
		CA 2193691 A	28-12-1995
		CA 2193692 A	28-12-1995
		CN 1151157 A	04-06-1997
		EP 0766664 A	09-04-1997
		EP 0766665 A	09-04-1997
		FI 965153 A	20-12-1996
		WO 9535275 A	28-12-1995
		GB 2303850 A,B	05-03-1997
		GB 2303629 A,B	26-02-1997
		JP 10501806 T	17-02-1998
		JP 10507158 T	14-07-1998
		NO 965515 A	20-02-1997
		NZ 288299 A	26-06-1998
WO 9602240 A	01-02-1996	EP 0769939 A	02-05-1997
		JP 10502656 T	10-03-1998
WO 9705865 A	20-02-1997	AU 6951296 A	05-03-1997
		CA 2229098 A	20-02-1997
		EP 0845987 A	10-06-1998
		AU 6764396 A	05-03-1997
		CA 2229044 A	20-02-1997
		EP 0871710 A	21-10-1998
		WO 9706242 A	20-02-1997
EP 757984 A	12-02-1997	JP 9104672 A	22-04-1997
EP 606046 A	13-07-1994	US 5455258 A	03-10-1995
		AT 159012 T	15-10-1997
		AU 684255 B	11-12-1997
		AU 5265593 A	04-05-1995
		CA 2112779 A	07-07-1994
		DE 69314456 D	13-11-1997
		DE 69314456 T	26-02-1998
		DK 606046 T	04-05-1998
		ES 2107648 T	01-12-1997
		FI 940012 A	07-07-1994
		GR 3025611 T	31-03-1998
		HU 70536 A	30-10-1995
		JP 6256293 A	13-09-1994
		MX 9400276 A	29-07-1994
		NO 940038 A,B,	07-07-1994
		NZ 250517 A	26-10-1995
		SG 42933 A	17-10-1997
		US 5506242 A	09-04-1996
		US 5552419 A	03-09-1996
		US 5646167 A	08-07-1997
		US 5672615 A	30-09-1997
		ZA 9400048 A	11-08-1994
WO 9809934 A	12-03-1998	AU 4159597 A	26-03-1998
WO 9744315 A	27-11-1997	AU 2680397 A	09-12-1997

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.